{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:20:47Z","timestamp":1790763647621,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021J01701"],"award-info":[{"award-number":["2021J01701"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejps.2024.106777","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T02:58:45Z","timestamp":1713668325000},"page":"106777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1517-5227","authenticated-orcid":false,"given":"Li-Mian","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106777_bib0026","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1389200221666200514130441","article-title":"Model-based Meta-analysis to Compare Primary Efficacy-endpoint, Efficacy-time Course, Safety, and Tolerability of Opioids Used in the Management of Osteoarthritic Pain in Humans","volume":"21","author":"Alhaj-Suliman","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106777_bib0015","doi-asserted-by":"crossref","first-page":"e13744","DOI":"10.1111\/ijcp.13744","article-title":"Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: a systematic review and meta-analysis of randomised controlled trials","volume":"75","author":"Alyoubi","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejps.2024.106777_bib0028","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/01.j.pain.0000460358.01998.15","article-title":"Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?","volume":"156","author":"Attal","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2024.106777_bib0012","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jdi.13013","article-title":"Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients","volume":"10","author":"Baba","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejps.2024.106777_bib0014","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40122-020-00156-6","article-title":"Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: a Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study","volume":"9","author":"Baba","year":"2020","journal-title":"Pain Ther."},{"key":"10.1016\/j.ejps.2024.106777_bib0009","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1523\/JNEUROSCI.21-16-06095.2001","article-title":"Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells","volume":"21","author":"Barclay","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejps.2024.106777_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/psp4.12041","article-title":"The Many Flavors of Model-Based Meta-Analysis: part I-Introduction and Landmark Data","volume":"5","author":"Boucher","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106777_bib0010","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1074\/jbc.M308778200","article-title":"entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse","volume":"279","author":"Brill","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.ejps.2024.106777_bib0023","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ejps.2024.106777_bib0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","article-title":"Overview of model-building strategies in population PK\/PD analyses: 2002-2004 literature survey","volume":"64","author":"Dartois","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106777_bib0027","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/WNL.65.12_suppl_4.S7","article-title":"Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain","volume":"65","author":"Dworkin","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2024.106777_bib0006","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.117.247551","article-title":"Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the \u03b12\u03b4 Subunit of Voltage-Gated Calcium Channels","volume":"365","author":"Domon","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106777_bib0004","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1111\/j.1526-4637.2011.01160.x","article-title":"New developments in the treatment algorithm for peripheral neuropathic pain","volume":"12","author":"de Leon-Casasola","year":"2011","journal-title":"Pain Med"},{"key":"10.1016\/j.ejps.2024.106777_bib0008","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","article-title":"Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin","volume":"103","author":"Field","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ejps.2024.106777_bib0020","unstructured":"Higgins J., Thomas J., Chandler J., Cumpston, M., Li, T., Page, M., Welch, V. (Eds.), 2021. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). https:\/\/training.cochrane.org\/handbook\/archive\/v6.2."},{"key":"10.1016\/j.ejps.2024.106777_bib0022","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106777_bib0013","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","article-title":"Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients","volume":"160","author":"Kato","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2024.106777_bib0005","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1080\/14656566.2021.1958780","article-title":"A review of a new voltage-gated Ca2+ channel \u03b12\u03b4 ligand, mirogabalin, for the treatment of peripheral neuropathic pain","volume":"22","author":"Kato","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2024.106777_bib0007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","article-title":"Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation","volume":"125","author":"Li","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2024.106777_bib0016","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/clpt.2011.242","article-title":"Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106777_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-based meta-analysis: an important tool for making quantitative decisions during drug development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106777_bib0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejps.2024.106777_bib0024","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2024.106777_bib0002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00540-018-2501-0","article-title":"Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians","volume":"32","author":"Sumitani","year":"2018","journal-title":"J. Anesth."},{"key":"10.1016\/j.ejps.2024.106777_bib0003","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jpainsymman.2016.09.015","article-title":"Topical Treatment of Peripheral Neuropathic Pain: applying the Evidence","volume":"53","author":"Sommer","year":"2017","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.ejps.2024.106777_bib0011","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2337\/dc14-1044","article-title":"Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejps.2024.106777_bib0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/(SICI)1097-0258(19990315)18:5<601::AID-SIM48>3.0.CO;2-L","article-title":"Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. II: a bootstrap modification of standard two-stage (STS) method for phase I trial","volume":"18","author":"Yafune","year":"1999","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejps.2024.106777_bib0001","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/molecules25051120","article-title":"Building and Testing PPAR\u03b3 Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain","volume":"25","author":"Westlund","year":"2020","journal-title":"Molecules"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:08:08Z","timestamp":1715069288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"alternative-id":["S0928098724000885"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106777","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106777"}}